BioNTech Investor Day Presentation Deck
iNeST I Autogene cevumeran (BNT122)
Neoantigen vaccines are well suited for the early-line setting
Normal
DNA
U
1000000000
00000000000
Tumor
DNA
Adjuvant
Residual cancer cells may remain -
emphasis on recurrence free survival
Tumor mass
Tumor resistance mechanisms
Immune system health
iNeST is being developed in collaboration with Genentech.
Early line
(adjuvant/first line)
Low tumor burden
Not fully established.
Functional T cell responses inducible.
●
1L metastatic
●
Rapidly growing but often still in
early phase of metastases
●
O
Three trials ongoing in early lines:
Advanced melanoma (Phase 2)
Adjuvant colorectal cancer (Phase 2)
Adjuvant pancreatic ductal adenocarcinoma (Phase 1)
NUM
Late-line metastatic
mRNA cancer vaccines
Bulky tumors with multiple
organs involved
Late line
(refractory)
Large bulky tumors
Multiple resistance mechanisms.
Higher rate of
dysfunctional immune cells.
BIONTECH
99View entire presentation